Clinical course and prognostic factors following bone recurrence from breast cancer

被引:209
作者
Coleman, RE
Smith, P
Rubens, RD
机构
[1] Weston Pk Hosp, YCRC Dept Clin Oncol, Sheffield S10 2SJ, S Yorkshire, England
[2] Guys Hosp, Imperial Canc Res Fund, Clin Oncol Unit, London SE1 9RT, England
关键词
D O I
10.1038/bjc.1998.52
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Three hundred and sixty-seven women presenting to the Breast Unit at Guy's Hospital between 1975 and 1990 whose first distant metastasis was in the skeleton were identified and the influence of a number of patient and tumour characteristics on the development and subsequent prognosis of bone metastases was assessed. One hundred and thirty-nine women had disease that remained clinically confined to the skeleton. They were more likely to be older, with lobular carcinoma and to have presented initially with little or no axillary lymph node involvement. The 228 women who subsequently developed disease at extra-osseus sites were more likely to have poorly differentiated ductal tumours and heavy lymph node involvement at primary diagnosis. On multivariate analysis, the clinical and pathological factors of greatest prognostic importance for survival after the development of bone metastases were histological grade (P = <0.0001), oestrogen receptor status (P = <0.0001), bone disease at initial presentation (P = <0.0001), disease-free interval (P = 0.002) and age (P = 0.006).
引用
收藏
页码:336 / 340
页数:5
相关论文
共 17 条
[1]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[2]   Use of bisphosphonates in cancer patients [J].
Body, JJ ;
Coleman, RE ;
Piccart, M .
CANCER TREATMENT REVIEWS, 1996, 22 (04) :265-287
[3]   PARATHYROID-HORMONE RELATED PROTEIN AND SKELETAL MORBIDITY IN BREAST-CANCER [J].
BUNDRED, NJ ;
WALKER, RA ;
RATCLIFFE, WA ;
WARWICK, J ;
MORRISON, JM ;
RATCLIFFE, JG .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :690-692
[4]   THE CLINICAL COURSE OF BONE METASTASES FROM BREAST-CANCER [J].
COLEMAN, RE ;
RUBENS, RD .
BRITISH JOURNAL OF CANCER, 1987, 55 (01) :61-66
[5]   Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial [J].
Conte, PF ;
Latreille, J ;
Mauriac, L ;
Calabresi, F ;
Santos, R ;
Campos, D ;
Bonneterre, J ;
Francini, G ;
Ford, JM .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) :2552-2559
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases [J].
Hortobagyi, GN ;
Theriault, RL ;
Porter, L ;
Blayney, D ;
Lipton, A ;
Sinoff, C ;
Wheeler, H ;
Simeone, JF ;
Seaman, J ;
Knight, RD ;
Heffernan, M ;
Reitsma, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (24) :1785-1791
[8]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[9]  
KING RJB, 1979, STEROID RECEPTOR ASS, P55
[10]   STEROID-HORMONE RECEPTOR ACTIVITY OF PRIMARY HUMAN BREAST-CANCER AND PATTERN OF 1ST METASTASIS [J].
KOENDERS, PG ;
BEEX, LVAM ;
LANGENS, R ;
KLOPPENBORG, PWC ;
SMALS, AGH ;
BENRAAD, TJ .
BREAST CANCER RESEARCH AND TREATMENT, 1991, 18 (01) :27-32